Loading...
DOCUMENTS
18
NOTICES
31
MOTS CLES
Safety
MORTALITY
Inclusion
Colonic epithelial primary cells
Microbiote
Colectomy
Disease Progression
Anti-TNF
HIV
Ustekinumab
Biologics
Cancer
Ulcerative colitis
Kidney diseases
Eligibility
Crohn’s disease
Epigénétiques
Disease progression
Surgery
Colorectal cancer
Endoscopic treatment
Survival
Tuberculosis
Consensus
Biomarker
Contraindication
Clinical guidelines
Helicobacter pylori
IL12
Neoadjuvant chemotherapy
Stricture
T1118 translocation
Inhibitor
Heart disease risk factors
Disability
Bactéries
Méthylation
CARCINOGENESIS
Epigenetics
Alkylating agents
Genes
RISK
Screening
Patient-reported outcome
Résistance
DNA methylation
Rituximab plus chlorambucil
Dysbiosis
Intestinal crypts
Anti-TNF agents
Crohn's disease
PCR
Inflammatory bowel diseases
Colon cancer
Methylation
Maintenance therapy
Inflammatory bowel disease
Bacteria
Monitoring
Therapeutics
Effectiveness
Gene methylation
Drug
IBD
MICROBIOTA
Algorithm
Tailored therapy
Inflammatory Bowel Diseases
Acceptability
MALT
Patients experience
Resistance
Eradication
IL23
Gene expression
MARKER
Parvimonas micra
Upper gastrointestinal tract
Dysbiose
Immunosuppressant
Microbiota
Éradication
COLON-CANCER
DNA METHYLATION
Rituximab
Cell adhesion
Fecal microbiota
18 FDG-PET/CT
Original Article Clinical
Vedolizumab
Gènes
Thérapie ciblée
Venous thromboembolism
Small molecules
Colon
Clinical trial
Primary sclerosing cholangitis
Cost effectiveness
Over 80s
Early detection of Colon Cancer using Molecular Markers and Microbiota , EA 7375 | |
---|---|
Institutions |
UPEC |
Adresse |
Université Paris-Est Créteil Groupe Hospitalier Henri Mondor Service de Gastroentérologie 51 Av Maréchal de Lattre de Tassigny 94010 Créteil cedex |
Courriel |
|
Site Internet |
|
Rattachement(s) |
|
Direction |
Aurélien AMIOT |
Adjoint |
Iradj SOBHANI |
Axe(s) de recherche
|
Le laboratoire axe ses recherches sur le rôle du microbiome intestinal ainsi que des changements épigénétiques dans l'intestin afin :
|